Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EOS884448 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Multiple Ascending Dose | EXPERIMENTAL | Dose escalation according to cohort allocation |
| Name | Type | Description |
|---|---|---|
| EOS884448 | DRUG | Multiple Ascending Dose |
Inclusion Criteria: 1. Be willing to provide a signed written informed consent for the trial and consent for biopsies before and during administration of EOS884448 2. Be more than18 years of age on day of signing informed consent. 3. Have histologically or cytologically confirmed advanced or metast...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
EOS884448 is an investigational small molecule being studied for the treatment of advanced cancer. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with advanced cancers who are at least 18 years old.
EOS884448 is being developed by iTeos Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ITOS. The company is conducting clinical research on this investigational oncology drug candidate.
EOS884448 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is still in the early stages of clinical testing for advanced cancer.
EOS884448 has one completed Phase 1 clinical trial, identified as NCT04335253. This first-in-human study enrolled 40 participants with advanced cancers and was conducted in Belgium. The trial was not randomized, double-blind, or controlled, and did not use biomarker selection.
No alternative names for EOS884448 have been reported. The drug is known only by this identifier in clinical development. It is a small molecule being investigated by iTeos Therapeutics for advanced cancer.